Liquidia (NASDAQ:LQDA) Issues Earnings Results, Misses Estimates By $0.07 EPS

Liquidia (NASDAQ:LQDA) announced its earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07), Zacks reports. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

Liquidia Stock Performance

Shares of LQDA stock opened at $14.92 on Thursday. The firm’s 50-day moving average is $14.67 and its 200-day moving average is $12.12. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -9.15 and a beta of 0.07. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.99.

Insider Activity

In other Liquidia news, CEO Roger Jeffs sold 22,343 shares of the stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the transaction, the chief executive officer now directly owns 1,019,177 shares of the company’s stock, valued at $12,005,905.06. This represents a 2.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the transaction, the general counsel now directly owns 573,478 shares in the company, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,245 shares of company stock valued at $843,326. 30.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on LQDA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of Liquidia in a research note on Thursday, January 9th. Wells Fargo & Company started coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Liquidia presently has an average rating of “Buy” and an average target price of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).